Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
ALLR | US
-0.10
-5.78%
Healthcare
Biotechnology
30/06/2024
21/10/2024
1.63
1.75
1.80
1.53
Allarity Therapeutics Inc. a clinical-stage biopharmaceutical company engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone) a selective microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis a liposomal formulation of cisplatin which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111 a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company was incorporated in 2004 and is headquartered in Boston Massachusetts.
View LessLow Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
106.9%1 month
98.5%3 months
136.3%6 months
131.3%-
-
0.12
0.07
0.04
-0.08
-
-
-16.89M
2.30M
2.30M
-
-
-
-
-121.82
0.15
10.03
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.74
Range1M
1.04
Range3M
3.84
Rel. volume
0.60
Price X volume
270.17K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
ZVSA | ZVSA | Biotechnology | 2.3 | 2.47M | 0.00% | 0.00 | 0.00% |
Dermata Therapeutics Inc. Common Stock | DRMA | Biotechnology | 1.56 | 2.36M | -3.11% | n/a | 0.00% |
Altamira Therapeutics Ltd. | CYTO | Biotechnology | 0.5751 | 2.17M | -2.53% | 0.32 | 1.54% |
60 Degrees Pharmaceuticals Inc. Common Stock | SXTP | Biotechnology | 1.07 | 1.99M | -1.83% | n/a | 5.19% |
Sorrento Therapeutics Inc | SRNE | Biotechnology | 0.003 | 1.90M | 11.11% | n/a | -101.21% |
Panbela Therapeutics Inc | PBLA | Biotechnology | 0.3354 | 1.76M | 5.14% | 0.00 | -39.69% |
Kiromic BioPharma Inc | KRBP | Biotechnology | 1.1 | 1.70M | -8.33% | n/a | -258.59% |
Innovation Pharmaceuticals Inc | IPIX | Biotechnology | 0.003 | 1.56M | 200.00% | n/a | 20.48% |
CohBar Inc | CWBR | Biotechnology | 0.5 | 1.45M | 0.00% | n/a | 0.00% |
Arch Therapeutics Inc | ARTH | Biotechnology | 0.3002 | 1.33M | 0.00% | n/a | 0.00% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 3.65 | 2.01M | -6.89% | n/a | 0.00% |
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.011 | 1.01M | 10.00% | n/a | -37.05% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -0.08 | 0.53 | Cheaper |
Ent. to Revenue | - | 3,967.00 | - |
PE Ratio | - | 41.03 | - |
Price to Book | 0.12 | 15.55 | Cheaper |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 136.28 | 72.80 | Riskier |
Debt to Equity | 0.07 | -1.23 | Expensive |
Debt to Assets | 0.04 | 0.25 | Cheaper |
Market Cap | 2.30M | 3.66B | Emerging |